Switch theme
Sign up to access all valuation multiples
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
1990
61
LTM Revenue $74.3M
LTM EBITDA -$112M
$16.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nektar Therapeutics has a last 12-month revenue (LTM) of $74.3M and a last 12-month EBITDA of -$112M.
In the most recent fiscal year, Nektar Therapeutics achieved revenue of $98.4M and an EBITDA of -$86.7M.
Nektar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nektar Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $74.3M | XXX | $98.4M | XXX | XXX | XXX |
| Gross Profit | $51.4M | XXX | $67.7M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | -$112M | XXX | -$86.7M | XXX | XXX | XXX |
| EBITDA Margin | -151% | XXX | -88% | XXX | XXX | XXX |
| EBIT | -$130M | XXX | -$130M | XXX | XXX | XXX |
| EBIT Margin | -175% | XXX | -132% | XXX | XXX | XXX |
| Net Profit | -$141M | XXX | -$119M | XXX | XXX | XXX |
| Net Margin | -190% | XXX | -121% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nektar Therapeutics's stock price is $1.
Nektar Therapeutics has current market cap of $135M, and EV of $16.9M.
See Nektar Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.9M | $135M | XXX | XXX | XXX | XXX | $-0.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nektar Therapeutics has market cap of $135M and EV of $16.9M.
Nektar Therapeutics's trades at 0.2x EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Nektar Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nektar Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Nektar Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $135M | XXX | $135M | XXX | XXX | XXX |
| EV (current) | $16.9M | XXX | $16.9M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNektar Therapeutics's last 12 month revenue growth is -46%
Nektar Therapeutics's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $3.2M for the same period.
Nektar Therapeutics's rule of 40 is -315% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nektar Therapeutics's rule of X is -265% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nektar Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -46% | XXX | -36% | XXX | XXX | XXX |
| EBITDA Margin | -151% | XXX | -88% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -315% | XXX | -134% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -265% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 123% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 201% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nektar Therapeutics acquired XXX companies to date.
Last acquisition by Nektar Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Nektar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nektar Therapeutics founded? | Nektar Therapeutics was founded in 1990. |
| Where is Nektar Therapeutics headquartered? | Nektar Therapeutics is headquartered in United States of America. |
| How many employees does Nektar Therapeutics have? | As of today, Nektar Therapeutics has 61 employees. |
| Who is the CEO of Nektar Therapeutics? | Nektar Therapeutics's CEO is Mr. Howard W. Robin. |
| Is Nektar Therapeutics publicy listed? | Yes, Nektar Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Nektar Therapeutics? | Nektar Therapeutics trades under NKTR ticker. |
| When did Nektar Therapeutics go public? | Nektar Therapeutics went public in 1994. |
| Who are competitors of Nektar Therapeutics? | Similar companies to Nektar Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nektar Therapeutics? | Nektar Therapeutics's current market cap is $135M |
| What is the current revenue of Nektar Therapeutics? | Nektar Therapeutics's last 12 months revenue is $74.3M. |
| What is the current revenue growth of Nektar Therapeutics? | Nektar Therapeutics revenue growth (NTM/LTM) is -46%. |
| What is the current EV/Revenue multiple of Nektar Therapeutics? | Current revenue multiple of Nektar Therapeutics is 0.2x. |
| Is Nektar Therapeutics profitable? | Yes, Nektar Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nektar Therapeutics? | Nektar Therapeutics's last 12 months EBITDA is -$112M. |
| What is Nektar Therapeutics's EBITDA margin? | Nektar Therapeutics's last 12 months EBITDA margin is -151%. |
| What is the current EV/EBITDA multiple of Nektar Therapeutics? | Current EBITDA multiple of Nektar Therapeutics is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
